| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Apollomics GAAP EPS of -$7.57, revenue of $8.5M | 1 | Seeking Alpha | ||
| APOLLOMICS Aktie jetzt für 0€ handeln | |||||
| Mo | Apollomics Inc. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 24.04. | Apollomics Inc. - 20-F, Annual and transition report of foreign private issuers | - | SEC Filings | ||
| 01.04. | Apollomics Inc. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 01.04. | Apollomics Inc. Announces $2.0 Million Bridge Financing | 1 | GlobeNewswire (USA) | ||
| 02.02. | Apollomics Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 23.12.25 | Apollomics H1 Loss Narrows | 2 | RTTNews | ||
| 22.12.25 | Apollomics GAAP EPS of -$11.37 | 3 | Seeking Alpha | ||
| 22.12.25 | Apollomics Inc.: Apollomics Reports First Half 2025 Financial Results | 163 | GlobeNewswire (Europe) | FOSTER CITY, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) ("Apollomics" or the "Company"), a late-stage clinical biopharmaceutical company developing multiple oncology... ► Artikel lesen | |
| 22.12.25 | Apollomics Inc. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 12.12.25 | Apollomics Inc. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 19.11.25 | Apollomics Inc.: Apollomics Announces Settlement of Cayman Litigation | 170 | GlobeNewswire (Europe) | FOSTER CITY, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. ("Apollomics" or the "Company") (Nasdaq: APLM) announced today entering into a settlement agreement (the "Settlement Agreement"... ► Artikel lesen | |
| 18.11.25 | Apollomics Inc. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 18.11.25 | Apollomics appoints Dr. Ya-Chi Huang to board following resignation | 2 | Investing.com | ||
| 18.11.25 | Apollomics Inc.: Apollomics Announces Changes to its Board of Directors and Composition of Committees | 1 | GlobeNewswire (USA) | ||
| 15.10.25 | Apollomics Inc.: Apollomics Announces Continued Listing on The Nasdaq Stock Market Following Hearing Cancellation | 231 | GlobeNewswire (Europe) | FOSTER CITY, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) ("Apollomics" or the "Company"), a California based late-stage clinical biopharmaceutical company developing multiple... ► Artikel lesen | |
| 14.10.25 | Apollomics Inc.: Apollomics, Inc. Company Operational Continuity Update | 205 | GlobeNewswire (Europe) | FOSTER CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) ("Apollomics" or the "Company"), today announced the following company operational update. Apollomics is a clinical-stage... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 88,20 | +0,06 % | BioNTech vor Wendepunkt: Diese Zahlen entscheiden jetzt | BioNTech steht nach dem Rückgang des Corona-Geschäfts vor einem strategischen Umbruch und richtet seinen Fokus zunehmend auf die Onkologie. Investoren blicken gespannt auf kommende Quartalszahlen und... ► Artikel lesen | |
| EVOTEC | 5,240 | +4,70 % | EQS-News: Evotec SE: Evotec kündigt Wechsel im Finanzvorstand an | EQS-News: Evotec SE
/ Schlagwort(e): Sonstiges
Evotec kündigt Wechsel im Finanzvorstand an
24.04.2026 / 07:30 CET/CEST
Für den Inhalt der Mitteilung ist der Emittent... ► Artikel lesen | |
| AMGEN | 295,45 | +0,14 % | Amgen hebt Jahresprognose an - Quartalszahlen etwa wie erwartet | THOUSAND OAKS (dpa-AFX) - Der US-Biotechkonzern Amgen blickt trotz zunehmender Konkurrenz zuversichtlicher auf das laufende Jahr. 2026 werde der Umsatz bei 37,1 bis 38,5 Milliarden Dollar liegen, teilte... ► Artikel lesen | |
| NANOREPRO | 1,515 | -0,98 % | Aktien KW 17 Märkte im Würgegriff. Planloser Trump , selbstbewusterer Iran. Lösungen müssen her. News. Rheinmetall. ITM Power. Porsche. The Platform Group. K+S. Bugatti. Circus. Surteco. NanoRepro. BB Biotech. Mensch und Maschine. ATOSS. MHP Hotel | Aktien - letzte Woche warteten die Märkte auf eine Lösung des Iran-Kriegs. Aber die Iraner sehen sich im Vorteil und Trump verlängert "auf unbestimmte Zeit" den Waffenstillstand. Aber die Strasse von... ► Artikel lesen | |
| BIOXXMED | 0,900 | -0,55 % | PTA-News: bioXXmed AG: Vollzug des Verkaufs der Rancoderm GmbH | DJ PTA-News: bioXXmed AG: Vollzug des Verkaufs der Rancoderm GmbH
Unternehmensmitteilung für den Kapitalmarkt
bioXXmed AG: Vollzug des Verkaufs der Rancoderm GmbH
Heidelberg (pta000/09.03.2026/13:50... ► Artikel lesen | |
| VIKING THERAPEUTICS | 25,600 | -3,58 % | Viking Therapeutics, Inc.: Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update | Conference call scheduled for 4:30 p.m. ET today
-- Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity Advance; VANQUISH-1 and VANQUISH-2 Trials Fully Enrolled... ► Artikel lesen | |
| SIRONA BIOCHEM | 0,037 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 24.04.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 24.04.2026.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 24.04.2026.ISIN NameCA46658Y1034 J2... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,320 | -5,04 % | Defence Therapeutics Inc.: Defence Therapeutics Announces Grant of Restricted Stock Units | Montreal, Quebec--(Newsfile Corp. - April 24, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), a publicly traded biotechnology and precision... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,370 | +1,09 % | US-Expansion im Fokus: NurExone richtet den Blick auf den weltweit größten Biotechmarkt | ||
| ABIVAX | 98,65 | -0,45 % | EQS-News: ABIVAX: Abivax to Present Data on Obefazimod at Digestive Disease Week | EQS-News: ABIVAX
/ Key word(s): Conference
Abivax to Present Data on Obefazimod at Digestive Disease Week
22.04.2026 / 22:05 CET/CEST
The issuer is solely responsible... ► Artikel lesen | |
| IBIO | 1,390 | -3,81 % | iBio (IBIO) Receives Regulatory Clearance to Initiate Phase 1 Trial of IBIO-600 | ||
| REDHILL BIOPHARMA | 1,090 | +0,93 % | RedHill Biopharma Ltd.: RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights | 2025 was a year of tenacity, strategic transactions and building traction for RedHill
Talicia® business transformed:
Formation of Talicia Holdings Inc. (THI) and... ► Artikel lesen | |
| ARROWHEAD PHARMACEUTICALS | 61,20 | -2,27 % | JPMorgan initiates Arrowhead Pharma stock coverage with overweight rating | ||
| VOYAGER THERAPEUTICS | 3,200 | +0,82 % | Voyager Therapeutics, Inc.: Voyager IV-Delivered CNS Gene Therapies Featured in Multiple Presentations at ASGCT 2026, Including Late Breaker on Tau-Targeted VY1706 for Alzheimer's Disease | ||
| CELLECTIS | 3,464 | +3,16 % | Cellectis Presents Epigenetic Editing Platform to Turn Genes Off Without Altering DNA at the ASGCT Annual Meeting |